Objective: Osteoclasts are bone-resorbing multinucleated cells derived from the monocyte/macrophage lineage during normal and pathological bone turnover. Recently, several studies revealed that alpha-tocopheryl succinate (αTP-suc) have demonstrated potent anti-cancer activities in vitro and in vivo. However, the effects of αTP-suc on osteoclast formation and bone resorption remain unknown. Thus, in this study, we examined the effects of αTP-suc on osteoclast differentiation and bone resorbing activity in inflammatory bone loss model. Methods: Osteoclast differentiation assay was performed by cocultures of mouse bone marrow cells and calvarial osteoblasts in culture media including interleukin-1 (IL-1). Osteoclasts were stained for tartrate-resistant acid phosphatase (TRAP). The level of receptor activator of nuclear factor-kappaB ligand (RANKL) mRNA was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). ICR mice were administered an intraperitoneal injections of αTP-suc or dimethyl sulfoxide (DMSO) 1 day before the implantation of a freeze-dried collagen sponge loaded with phosphate-buffered saline (PBS) or IL-1 over the calvariae and every other day for 7 days. The whole calvariae were obtained and analyzed by micro-computed tomography (CT) scanning, and stained for TRAP. Results: αTP-suc inhibits osteoclast formation in cocultures stimulated by IL-1 and decreased the level of expression of RANKL mRNA in osteoblasts. In addition, administered intraperitoneal injections of αTP-suc prevented IL-1-mediated osteoclast formation and bone loss in vivo. Conclusion: Our findings suggest that αTP-suc may have therapeutic value for treating and preventing bone-resorptive diseases, such as osteoporosis.
INTRODUCTION
The bone tissue forms cartilages and the skeletal system, supports and adheres muscles with its mechanical functions, protects organic system and bone marrows and preserve them to maintain the homeostasis of calcium and phosphoric ions. The bone tissue consists of various cells including collagen, cytoplasmic matrix like glycoprotein, osteoblasts, osteoclasts and osteocytes. In addition, the bone tissue is continuously dissembled a little bit, generates new bones in proportion to the dissembled bones and is a very dynamic organ which maintains the homeostasis. The bone remodeling is maintained through proper balance between bone resorption by osteoclasts derived from the hematopoietic stem cell and bone formation by osteoblasts derived from the mesenchymal stem cell inside the marrow. [1, 2] Overactive osteoclast causes imbalance the bone remodeling and metabolic bone diseases including periodontal disease by bacterial/germ infection, as well as osteoporosis, metastatic cancer by tumors, rheumatic arthritis and degenerative arthritis. [3, 4] The receptor activator of nuclear factorkappaB ligand (RANKL) is produced from the osteoblast by inflammatory cytokine like interleukin-1 (IL-1), becomes a crucial factor in creating and activating the osteoclast and plays a crucial role in differentiation from osteoclast precursors into mature osteoclasts under the existence of macrophage colony-stimulating factor (M-CSF). [5] [6] [7] Recently, Xiong et al. [8] reported that RANKL produced from osteocytes and chondrocytes in the substrate were essential for both osteoclast formation and its activation. In addition, the RANKL activates various signaling pathways by binding with RANKL expressed from the osteoclast precursors and is known as a requirement for differentiating and activating the osteoclasts. [3] The structural formula of vitamin E was firstly reported in 1922 and is known as playing an important role in the reproduction process. [9] The vitamin E consists of tocopherol and tocotrienol depending on the existence of saturation in the site chain and has the types of alpha, beta, gamma and delta. The four types are separated depending on the numbers and locations of methyl groups in the chromanol ring structure. [10] The alpha (α)-tocopherol is abundant in human body and the vitamin E is the most representing substance. That is why the material has been under many researches but its biological studies have not been emerged. For example, the gamma (γ)-tocopherol decreases the cyclooxygenase-2 (COX-2) activation in the macrophages treated with the lipopolysaccharide (LPS) and epithelial cells treated with IL-1 and inhibits the creation of prostaglandin E 2 (PGE 2 ) but not much by α-tocopherol. [11] Aggarwal et al. [10] reported that the tocotrienols with different types increase anti-cancer and nerve cell protection effects but not by α-tocopherol. Meanwhile, Prasad and Edwards-Prasad [12] reported that the α-tocopheryl succinate (αTP-suc), one of esterified compound of the vitamin E was the most effective in anti-cancer activities than other vitamin E derivants including α-TP acetate and α-TP nicotinate. In addition, it was reported that cancer treatment was improved by using αTP-suc assistant while performing radiation and chemotherapy. [13] Recently, we found that α-tocotrienol strongly inhibited bone resorption and osteoclast formation by inhibiting the RANKL expression on the osteoblast but α-tocopherol had no such effect. [14] However, studies on the effects of αTP-suc in the aspect of generating and following bone reduction have been rare despite various advantages of αTP-suc mentioned above.
In this study, we seeks to discover how αTP-suc affected the osteoclast generation, the relation with the RANKL expression in the osteoblast known as an essential factor for the osteoclast generation and the effect of αTP-suc on the bone destruction stimulated by IL-1 in vivo.
MATERIALS AND METHODS

Material
Cell culture media and serum were purchased from Invitrogen (Carlsbad, CA, USA). The M-CSF, RANKL and IL-1 were purchased from PeproTech (London, UK) and 1α,25(OH) 2 D 3 , αTP-suc, α-tocopherol and αTP acetic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Osteoclast differentiation
The macrophages from the mouse bone marrow were obtained by the method mentioned in previous studies. [15] The macrophages were treated by the M-CSF (30 ng/mL) and the RANKL (100 ng/mL) for 4 days in the α-minimal essential medium (MEM) complete media which contained 10% (v/v) fetal bovine serum, 100 U/ml penicillin and 100 μg/mL streptomycin with the density of 4 × 10 
Reverse transcriptase-polymerase chain reaction (RT-PCR)
The RNA was prepared by using the TRIzol reagent 
IL-1-induced bone loss in vivo
All animal experiments were reviewed and approved by the Seoul National University School of Dentistry Animal Care Committee (Seoul, Korea). Lyophilized collagen sponge soaked with the IL-1 (2 μg) or the phosphatebuffered saline (PBS) was implanted to 5 mice in the test group and 5 mice in the control group (5-week old, male, ICR) on the calvarial bone to induce bone loss by IL-1. [16] The αTP-suc (80 mg/kg body weight) was intraperitoneally administered one day before implantation the collagen sponge and injected for 7 days for every 2 days after the operation. The same amount of αTP-suc, 30 μL of the DMSO solution, was intraperitoneally administered to the control group. All the mice were anesthetized 7 days after the operation, the calvarial bones were washed with the PBS and fixed with 4% of paraformaldehyde for one day.
The calvaria were analyzed with the methods mentioned in previous studies to achieve 3-dimensional (3D) images (VGstudio MAX 1.2.1 program; Volume Graphics, Heidelberg, Germany) using high resolution micro-CT (SMX-90CT system; Shimadzu, Kyoto, Japan). [17] The 3D image files were used to measure the bone mineral content (BMC) through the TRI/3D-VIE (RATOC System Engineering, Kyoto, Japan) program. In addition, the whole calvaria was stained by the TRAP solution and the number of osteoclasts per unit cancellous bone surface dyed with red was measured with the manufacturer's instruction using the OsteoMeasure XP Version 1.01 (OsteoMetrics, Decatur, GA, USA) program.
Statistical analysis
ll the data were expressed as the average ± the standard deviation and the differences were analyzed by the Student's t-test for 2 groups and the one-way ANOVA (SPSS statistical software version 12; SPSS Inc., Chicago, IL, USA) for more than 3 groups. The data with less than 0.05 of P were expressed with asterisk (*) for significance.
RESULTS
The effect of αTP-suc on the osteoclast differentiation induced by co-culture of osteoblasts and bone marrow cells
To investigate the effect of the αTP-suc on the osteoclast differentiation, the osteoblasts and bone marrow cells isolated from mice were co-cultured in the presence of IL-1 to induce osteoclast formation. The result of checking the osteoclast differentiation through the TRAP staining after cell cultures for 7 days with different concentrations of αTP-suc showed that the group treated with the αTP-suc significantly inhibited osteoclast formation dependent on concentration compared to the control group (Fig. 1A, 1B ).
Such inhibition of osteoclast differentiation did not appear in the α-tocopherol and αTP acetate (Fig. 1B) . As such, the αTP-suc may strongly inhibit the osteoclast differentiation induced by co-culture unlike different αTPs. Fig. 2A, 2B) . The results mean that αTP-suc did not directly affect the osteoclast precursors and the substance may inhibit the osteoclast differentiation by affecting the osteoblast.
The effect of αTP-suc on the RANKL expression in the osteoblasts
The RANKL is a member of tumour necrosis factor Fig. 3A and B) . The RANKL expression increased by stimulating factors of the osteoclast differentiation was strongly inhibited by the αTP-suc treatment but did not much affect the OPG expression (Fig. 3A, 3B ). As well, αTP-suc did not affect the expression and generation of M-CSF, COX-2 and PGE 2 . These results show that the inhibition of the osteoclast differentiation by αTP-suc was directly related to inhibiting the RANKL expression in the osteoblast.
The effect of αTP-suc on IL-1-induced bone destruction in vivo
It was confirmed that the αTP-suc inhibited the osteoclast formation in vitro studies. Next, we investigated the effect 
IL-1 is a strong cytokine related to inflammation and it was
shown that treating the IL-1 lead to severe calvarial bone loss through the TRAP satining (Fig. 4A, top) and micro-CT images (Fig. 4A, bottom) but the mice injected with αTP-suc showed strong inhibition of bone losses due to the IL-1 (Fig. 4A) . In addition, the BMC lost by the IL-1 was significantly restored by αTP-suc (Fig. 4B ) and the number of TRAP-positive osteoclasts per unit area increased by the IL-1 was significantly decreased by αTP-suc (Fig. 4B) .
These results show that αTP-suc inhibited the osteoclast formation and its following bone losses in vivo like at the cell level.
DISCUSSION
The effect of αTP-suc on the bone biology, especially on the osteoclast differentiation and bone loss is rarely known even though it is reported that αTP-suc was the most effective in anti-cancer activities than other vitamin E derivants and very effective as the adjuvant to the cancer treatment. [13] Prior to the study, it was reported that α-tocotrienol, one of vitamin E series, inhibited the osteoclast generation and bone resorption. [14] The α-tocotrienol strongly inhibited the RANKL expression in the osteoblast, known as a critical factor in the osteoclast differentiation and the c-Fos expression in osteoclast precursors. In addition, inhibiting differentiation to mature osteoclasts from the osteoclast precursors by α-tocotrienol was completely restored by the excessive expression of the c-Fos. In addition, it was found out that α-tocotrienol strongly inhibited the bone resorption by the mature osteoclasts through the calcium-phosphate apatite-coated OAAS plate. [14] However, the other vitamin E series, α-tocopherol, did not show the osteoclast differentiation and the bone resorption. [14] Other study groups reported that the vitamin E was required for bone calcification and reformation and it was found out that α-tocotrienol was more effective in bone protection than α-tocopherol. [18] [19] [20] [21] Meanwhile, it was interesting that Fujita et al. [22] reported that the genetic mouse model of vitamin E by eliminating the α-tocopherol transfer protein showed increase in bone mass by decreasing bone resorption and the α-tocopherol treatment at the cell level The indicated protein amounts were determined by using enzyme Immunoassay (ELISA) kits in cell lysates (RANKL) and in cell culture media (osteoprotegerin and prostaglandin E 2 ). *P < 0.05. [24] reported that the mice with deficient IL-1 receptors did not show decrease in the bone mass due to the ovariectomy and Abramson and Amin [25] discovered that blocking the IL-1 signal system decreased bone destruction and cartilage losses in the animal model with rheumatic arthritis.
Interestingly, the αTP-suc strongly inhibited the RANKL expression increased by the IL-1 in the osteoblasts (Fig. 3) .
The IL-1 stimulated the PGE 2 generation and increased the induced by the IL-1 was not affected by the αTP-suc (Fig. 3 ).
In addition, the osteoclast differentiation by the αTP-suc and the RANKL expression inhibition were not restored by directly stimulating the PGE 2 into the cells (not published).
Therefore, the results suggest that the αTP-suc affected inhibited by the αTP-suc (Fig. 3) . Therefore, additional studies are required to discover whether the activation of the RANKL promoters induced by the IL-1 or the vitamin D is inhibited by the αTP-suc.
Lastly, we investigated whether the inhibition of osteoclast differentiation by αTP-suc in vitro was reproduced in the organism by using the mouse model. Injecting the αTP-suc strongly inhibited the excessive bone losses and the osteoclast formation on calvarial bone induced by IL-1.
The results coincide with the study results in vitro and may suggest the possibility that the RANKL expression may be inhibited in the osteoblast by the αTP-suc in vivo. However, additional studies are required to investigate whether the RANKL expression in vivo is inhibited by the αTP-suc. In addition, it was reported that the RANKL produced from the chondrocytes and ostecytes were required to form and activate the osteoclasts, [8] meaning that the effect of the αTP-suc on the RANKL expression from these cells shall be investigated.
CONCLUSION
The αTP-suc inhibited the osteoclast formation in the co-culture system which consisted of the osteoblasts and the bone marrow cells but failed to inhibit the differentiation of the osteoclast precursors to mature osteoclasts by the RANKL. Also, the αTP-suc decreased the RANKL expression in the osteoblasts. This study confirmed the osteoclast formation and bone destruction inhibition by the αTP-suc in vivo using the mouse model. Therefore, this study results indicated that the αTP-suc may be efficiently utilized to prevent and treat metabolic bone diseases including the osteoporosis due to excessive bone losses. 2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases.
